Anavex Announces Panel Discussion and Presentation at OneMedForum Conference

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

Anavex to Present at Biotech Showcase 2015 in San Francisco

Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

Anavex Upgrades to OTCQX Marketplace

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference

Anavex to Present at SeeThruEquity Investor Conference in New York City

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease